JPWO2020259258A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020259258A5 JPWO2020259258A5 JP2021578171A JP2021578171A JPWO2020259258A5 JP WO2020259258 A5 JPWO2020259258 A5 JP WO2020259258A5 JP 2021578171 A JP2021578171 A JP 2021578171A JP 2021578171 A JP2021578171 A JP 2021578171A JP WO2020259258 A5 JPWO2020259258 A5 JP WO2020259258A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- alkyl
- seq
- amino acid
- drug conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910577909 | 2019-06-28 | ||
| CN201910577909.6 | 2019-06-28 | ||
| PCT/CN2020/094767 WO2020259258A1 (zh) | 2019-06-28 | 2020-06-05 | 一种抗体偶联药物、其中间体、制备方法及应用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022542222A JP2022542222A (ja) | 2022-09-30 |
| JP2022542222A5 JP2022542222A5 (https=) | 2023-06-26 |
| JPWO2020259258A5 true JPWO2020259258A5 (https=) | 2023-06-26 |
| JP7407845B2 JP7407845B2 (ja) | 2024-01-04 |
Family
ID=74059658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021578171A Active JP7407845B2 (ja) | 2019-06-28 | 2020-06-05 | 抗体薬物複合体、その中間体、製造方法及び使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220233708A1 (https=) |
| EP (1) | EP3991754A4 (https=) |
| JP (1) | JP7407845B2 (https=) |
| KR (1) | KR20220025861A (https=) |
| CN (1) | CN113766933B (https=) |
| AU (1) | AU2020301289B2 (https=) |
| BR (1) | BR112021026580A2 (https=) |
| CA (1) | CA3144790A1 (https=) |
| WO (1) | WO2020259258A1 (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020402006A1 (en) * | 2019-12-12 | 2022-07-07 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-claudin antibody-drug conjugate and pharmaceutical use thereof |
| CA3186295A1 (en) * | 2020-06-08 | 2021-12-16 | Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Camptothecin drug having high-stability hydrophilic connecting unit and conjugate thereof |
| WO2021252708A1 (en) * | 2020-06-11 | 2021-12-16 | President And Fellows Of Harvard College | Stabilized trioxacarcin antibody drug conjugates and uses thereof |
| EP4227309A4 (en) * | 2020-10-12 | 2024-11-27 | Sichuan Baili Pharmaceutical Co. Ltd. | DEUTERATED CAMPTOTHECIN DERIVATIVE AND ANTIBODY-DRUG CONJUGATE THEREOF |
| EP4257153B1 (en) * | 2020-12-04 | 2025-11-12 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Antibody-drug conjugate, and intermediate thereof, preparation method therefor, and application thereof |
| US20230416270A1 (en) * | 2020-12-11 | 2023-12-28 | Wigen Biomedicine Technology (shanghai) Co., Ltd. | Novel camptothecin derivative, composition comprising same and use thereof |
| EP4265274B1 (en) * | 2020-12-18 | 2025-03-19 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | B7-h3 targeting antibody-drug conjugate, and preparation method therefor and use thereof |
| KR20230121842A (ko) * | 2020-12-18 | 2023-08-21 | 상하이 후단-장지앙 바이오-파마슈티컬 컴퍼니 리미티드 | Trop2를 표적으로 하는 항체 약물 접합체, 이의 제조방법 및 용도 |
| CN114805377A (zh) * | 2021-01-29 | 2022-07-29 | 明慧医药（杭州）有限公司 | 适用于抗体-药物偶联物的毒素分子 |
| CN116888123B (zh) * | 2021-02-09 | 2026-02-24 | 微境生物医药科技(上海)有限公司 | 用于adc制备的喜树碱衍生物 |
| CN116897149A (zh) * | 2021-03-30 | 2023-10-17 | 上海复旦张江生物医药股份有限公司 | 一种连接基药物偶联物的制备方法及其中间体 |
| WO2022205111A1 (zh) * | 2021-03-31 | 2022-10-06 | 上海复旦张江生物医药股份有限公司 | 一种伊喜替康衍生物的制备方法及其中间体 |
| CN115385926B (zh) * | 2021-05-24 | 2025-06-03 | 上海复旦张江生物医药股份有限公司 | 一种连接基药物偶联物的制备方法及其中间体 |
| JP2024523422A (ja) * | 2021-06-17 | 2024-06-28 | ミンフイ ファーマシューティカル （ハンチョウ） リミテッド | 抗腫瘍化合物およびその応用 |
| TW202320858A (zh) | 2021-07-19 | 2023-06-01 | 美商薩諾管理公司 | 免疫接合物及方法 |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| CN117715913A (zh) * | 2021-07-19 | 2024-03-15 | 芝诺管理公司 | 免疫缀合物和方法 |
| KR20240040090A (ko) | 2021-07-30 | 2024-03-27 | 상하이 후단-장지앙 바이오-파마슈티컬 컴퍼니 리미티드 | 항-dll3 항체 및 이의 제조 방법, 이의 약물 접합체 및 용도 |
| WO2023042097A1 (en) * | 2021-09-15 | 2023-03-23 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate for use in methods of treating chemotherapy-resistant cancer |
| AU2022350588A1 (en) * | 2021-09-27 | 2024-05-02 | Evopoint Biosciences Co., Ltd. | Antibody, antibody-drug conjugate thereof and use thereof |
| CN118401258A (zh) * | 2021-12-09 | 2024-07-26 | 昆山新蕴达生物科技有限公司 | 一种亲和力改善的抗体-药物偶联物、其制备方法及应用 |
| KR20250009592A (ko) | 2022-04-12 | 2025-01-17 | 미네르바 바이오테크놀로지 코포레이션 | 항-가변 muc1* 항체 및 그의 용도 |
| CN118955615B (zh) * | 2022-07-05 | 2026-01-30 | 上海药明合联生物技术有限公司 | 偶联连接子 |
| EP4558506A1 (en) * | 2022-07-22 | 2025-05-28 | NJ Bio, Inc. | Hexacyclic topoisomerase inhibitors having cytotoxic activity on cancer cells |
| EP4562051A1 (en) * | 2022-07-26 | 2025-06-04 | Immunome, Inc. | Immunoconjugates and methods |
| KR20250049293A (ko) * | 2022-07-27 | 2025-04-11 | 밍훼이 파마슈티컬 (항저우) 리미티드 | 항체-약물 접합체 및 이의 용도 |
| CN117510515A (zh) * | 2022-07-28 | 2024-02-06 | 明慧医药（杭州）有限公司 | 适用于抗体-药物偶联物的毒素分子 |
| CN120417935A (zh) * | 2022-10-25 | 2025-08-01 | 默沙东有限责任公司 | 依喜替康衍生的adc接头-载荷及其药物组合物和用途 |
| EP4623936A1 (en) * | 2022-11-22 | 2025-10-01 | Keymed Biosciences (Chengdu) Co., Ltd. | Fused ring compound, conjugate thereof and use thereof |
| KR20250111373A (ko) * | 2022-11-25 | 2025-07-22 | 밍훼이 파마슈티컬 (항저우) 리미티드 | 항종양 화합물 및 이의 응용 |
| TW202426059A (zh) * | 2022-11-30 | 2024-07-01 | 大陸商正大天晴藥業集團股份有限公司 | 抗cldn18.2抗體藥物偶聯物及其藥物組合物和用途 |
| CN116217654B (zh) * | 2022-12-30 | 2025-09-26 | 上海复旦张江生物医药股份有限公司 | 一种连接基药物偶联物的制备方法及其中间体 |
| CN116217655B (zh) * | 2022-12-30 | 2025-09-23 | 上海复旦张江生物医药股份有限公司 | 一种连接基药物偶联物的中间体的制备方法 |
| CN116178386B (zh) * | 2022-12-30 | 2025-09-09 | 上海复旦张江生物医药股份有限公司 | 一种连接基药物偶联物的制备方法及其中间体 |
| EP4696332A1 (en) | 2023-04-10 | 2026-02-18 | Daiichi Sankyo Company, Limited | Combination of anti-b7-h3 antibody-drug conjugate with atr inhibitor or atm inhibitor |
| WO2025021152A1 (zh) * | 2023-07-26 | 2025-01-30 | 上海医药集团股份有限公司 | 喜树碱类小分子及其抗体药物偶联物、制备方法和应用 |
| WO2025049270A1 (en) * | 2023-08-25 | 2025-03-06 | Macrogenics, Inc. | B7-h3 antibody-drug conjugates |
| WO2025106278A1 (en) | 2023-11-17 | 2025-05-22 | Mersana Therapeutics, Inc. | Treatment of cancer using b7-h4-targeted antibody-drug conjugates |
| WO2025238587A1 (en) | 2024-05-16 | 2025-11-20 | Daiichi Sankyo Company, Limited | Combination of anti-b7-h3 antibody-drug conjugate and androgen receptor signaling inhibitor |
| CN120617538B (zh) * | 2025-07-21 | 2026-04-03 | 南京滴力生物科技有限公司 | 一种用于治疗肿瘤的抗体药物偶联物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8742076B2 (en) * | 2008-02-01 | 2014-06-03 | Genentech, Inc. | Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods |
| KR20200058590A (ko) * | 2008-04-30 | 2020-05-27 | 이뮤노젠 아이엔씨 | 가교제 및 그 용도 |
| AU2009320481C1 (en) * | 2008-11-03 | 2016-12-08 | Syntarga B.V. | Novel CC-1065 analogs and their conjugates |
| KR102557309B1 (ko) * | 2012-05-15 | 2023-07-20 | 씨젠 인크. | 자가-안정화 링커 접합체 |
| DK2907824T3 (en) * | 2012-10-11 | 2018-07-23 | Daiichi Sankyo Co Ltd | ANTIBODY-drug conjugate |
| SI3466976T1 (sl) * | 2014-01-31 | 2021-12-31 | Daiichi Sankyo Company, Limited | Anti-her2 konjugat protitelesa-zdravila |
| JP2017114763A (ja) | 2014-03-26 | 2017-06-29 | 第一三共株式会社 | 抗ｃｄ９８抗体−薬物コンジュゲート |
| EP3209334A2 (en) * | 2014-10-20 | 2017-08-30 | Igenica Biotherapeutics, Inc. | Novel antibody-drug conjugates and related compounds, compositions, and methods of use |
| TWI799438B (zh) * | 2017-08-10 | 2023-04-21 | 日商住友製藥股份有限公司 | 半星芒體衍生物及此等之抗體藥物複合體 |
| CN108853514B (zh) * | 2017-08-18 | 2022-07-22 | 四川百利药业有限责任公司 | 具有两种不同药物的抗体药物偶联物 |
| CN109106951A (zh) * | 2017-08-18 | 2019-01-01 | 四川百利药业有限责任公司 | 一种喜树碱-抗体偶联物 |
| CN109200291B (zh) * | 2018-10-24 | 2021-06-08 | 中国医学科学院医药生物技术研究所 | 一种靶向于egfr的抗体偶联药物及其制备方法和其用途 |
-
2020
- 2020-06-05 CA CA3144790A patent/CA3144790A1/en active Pending
- 2020-06-05 CN CN202080030918.4A patent/CN113766933B/zh active Active
- 2020-06-05 WO PCT/CN2020/094767 patent/WO2020259258A1/zh not_active Ceased
- 2020-06-05 BR BR112021026580A patent/BR112021026580A2/pt unknown
- 2020-06-05 EP EP20833007.6A patent/EP3991754A4/en active Pending
- 2020-06-05 US US17/622,500 patent/US20220233708A1/en active Pending
- 2020-06-05 JP JP2021578171A patent/JP7407845B2/ja active Active
- 2020-06-05 AU AU2020301289A patent/AU2020301289B2/en active Active
- 2020-06-05 KR KR1020227002873A patent/KR20220025861A/ko not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020259258A5 (https=) | ||
| TWI868726B (zh) | 抗體-藥物結合物之新穎製造方法 | |
| JPWO2020122034A5 (https=) | ||
| TWI843705B (zh) | 結晶及其改良製造方法、以及抗體-藥物結合物之改良製造方法 | |
| TWI906070B (zh) | 抗體-藥物結合物之用途 | |
| WO2022199237A1 (zh) | 修饰的氨基酸及其在adc中的应用 | |
| TW202435919A (zh) | 抗體-藥物結合物之有效的製造方法 | |
| CN113194983A (zh) | 用于治疗病毒感染的组合物及方法 | |
| TW202102225A (zh) | 抗her2抗體-吡咯并苯二氮呯衍生物結合物 | |
| TW202537975A (zh) | 抗體－藥物結合物之製造方法 | |
| JP2020513855A5 (https=) | ||
| JP2020524675A5 (https=) | ||
| CN112839683A (zh) | 含有标记部-抗人抗体Fab片段复合物的药物组合物 | |
| CN114569739A (zh) | 抗体药物偶联物 | |
| EP4633634A2 (en) | Novel camptothecin derivatives and conjugates thereof | |
| WO2024140433A2 (zh) | 含n-亚甲基酰胺连接子的抗体-药物偶联物 | |
| EA200501131A1 (ru) | Парентеральные композиции пептидов для лечения системной красной волчанки | |
| WO2019170686A1 (fr) | Composition vaccinale anti-pd-l1 | |
| CN114106088A (zh) | 基于溴甲基吡嗪的药物偶联物及adc | |
| JP2015529656A5 (https=) | ||
| CN115348874A (zh) | 蛋白质-抗病毒化合物偶联物 | |
| TW201839001A (zh) | 細胞毒性苯并二氮平衍生物及其綴合物 | |
| WO2017194390A1 (en) | Dimeric compounds | |
| CN115594732A (zh) | 一种连接基-药物偶联物、其制备方法及应用 | |
| WO2021256524A1 (ja) | 免疫原性低減型低分子抗体とその製造法 |